Trent JC - Search Results

1

Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.

Trent JC, Lazar AJ, Zhang W. Trent JC, et al. Future Oncol. 2007 Dec;3(6):629-37. doi: 10.2217/14796694.3.6.629. Future Oncol. 2007. PMID: 18041915 Review.

2

Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. Scaife CL, et al. Am J Surg. 2003 Dec;186(6):665-9. doi: 10.1016/j.amjsurg.2003.08.023. Am J Surg. 2003. PMID: 14672776

3

Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.

Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, Pollock R, Zhang W. Koh JS, et al. Histol Histopathol. 2004 Apr;19(2):565-74. doi: 10.14670/HH-19.565. Histol Histopathol. 2004. PMID: 15024716 Review.

4

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. Chen LL, et al. Among authors: trent jc. Cancer Res. 2004 Sep 1;64(17):5913-9. doi: 10.1158/0008-5472.CAN-04-0085. Cancer Res. 2004. PMID: 15342366

5

Update on the biology and therapy of gastrointestinal stromal tumors.

D'Amato G, Steinert DM, McAuliffe JC, Trent JC. D'Amato G, et al. Among authors: trent jc. Cancer Control. 2005 Jan-Feb;12(1):44-56. doi: 10.1177/107327480501200106. Cancer Control. 2005. PMID: 15668652 Free article. Review.

6

Imatinib mesylate in the treatment of gastrointestinal stromal tumour.

Steinert DM, McAuliffe JC, Trent JC. Steinert DM, et al. Among authors: trent jc. Expert Opin Pharmacother. 2005 Jan;6(1):105-13. doi: 10.1517/14656566.6.1.105. Expert Opin Pharmacother. 2005. PMID: 15709888 Review.

7

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Steinert DM, et al. Among authors: trent jc. Cancer. 2006 Apr 1;106(7):1617-23. doi: 10.1002/cncr.21781. Cancer. 2006. PMID: 16518826 Free article.

8

Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.

Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Hong X, et al. Among authors: trent jc. Radiographics. 2006 Mar-Apr;26(2):481-95. doi: 10.1148/rg.262055097. Radiographics. 2006. PMID: 16549611 Review.

9

New developments in gastrointestinal stromal tumor.

Trent JC, Benjamin RS. Trent JC, et al. Curr Opin Oncol. 2006 Jul;18(4):386-95. doi: 10.1097/01.cco.0000228747.02660.e2. Curr Opin Oncol. 2006. PMID: 16721136 Review.

10

Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.

Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Trent JC, et al. Cancer. 2006 Oct 15;107(8):1898-908. doi: 10.1002/cncr.22214. Cancer. 2006. PMID: 16986125 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters